TR201000687A1 - Effervescent formulations containing cefixime and clavulanic acid as active ingredient - Google Patents

Effervescent formulations containing cefixime and clavulanic acid as active ingredient

Info

Publication number
TR201000687A1
TR201000687A1 TR2010/00687A TR201000687A TR201000687A1 TR 201000687 A1 TR201000687 A1 TR 201000687A1 TR 2010/00687 A TR2010/00687 A TR 2010/00687A TR 201000687 A TR201000687 A TR 201000687A TR 201000687 A1 TR201000687 A1 TR 201000687A1
Authority
TR
Turkey
Prior art keywords
forms
clavulanic acid
active ingredient
formulations containing
effervescent formulations
Prior art date
Application number
TR2010/00687A
Other languages
Turkish (tr)
Inventor
Bi̇lgi̇ç Mahmut
Original Assignee
Bi̇lgi̇ç Mahmut
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bi̇lgi̇ç Mahmut filed Critical Bi̇lgi̇ç Mahmut
Priority to TR2010/00687A priority Critical patent/TR201000687A1/en
Priority to PCT/TR2011/000033 priority patent/WO2011093829A1/en
Priority to EP11712063A priority patent/EP2528586A1/en
Priority to PCT/TR2011/000026 priority patent/WO2011093822A1/en
Publication of TR201000687A1 publication Critical patent/TR201000687A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0007—Effervescent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Mevcut buluş, dirençli enfeksiyon tedavisinde kullanılmak üzere, sefiksim ve klavulanik asit ve/veya bunların farmasötik kabul edilebilir tuzları, hidratları, enantiomerleri, rasematları, organik tuzları, inorganik tuzları, esterleri, polimorfları, kristal formları ve amorf formları ve/veya bunların kombinasyonlarını içeren efervesan farmasötik formülasyonlar ile ilgilidir. Ayrıca, aktif bileşenler su içinde çözülmek sureti ile taze halde hastaya verildiğinden, süspansiyon formlara göre raf ömürleri daha uzun, biyoyararlanımları daha yüksektir. Bu şekilde hazırlanan efervesan formülasyonların kullanımı, tablet ve kapsül formlara kıyasla özelikle yaşlı ve çocuklar gibi yutma zorluğu yaşayan hastalarda daha kolaydır.The present invention is an effervescent composition comprising cefixime and clavulanic acid and / or pharmaceutically acceptable salts, hydrates, enantiomers, racemates, organic salts, inorganic salts, esters, polymorphs, crystalline forms and / or amorphous forms thereof and / or combinations thereof for use in the treatment of resistant infection. pharmaceutical formulations. Furthermore, since the active ingredients are dissolved in water and delivered to the patient in fresh form, their shelf life is longer and their bioavailability is higher than the suspension forms. Effervescent formulations prepared in this way are easier to use than tablets and capsule forms, particularly in patients with difficulty in swallowing, such as the elderly and children.

TR2010/00687A 2010-01-29 2010-01-29 Effervescent formulations containing cefixime and clavulanic acid as active ingredient TR201000687A1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
TR2010/00687A TR201000687A1 (en) 2010-01-29 2010-01-29 Effervescent formulations containing cefixime and clavulanic acid as active ingredient
PCT/TR2011/000033 WO2011093829A1 (en) 2010-01-29 2011-01-28 Effervescent formulations comprising cefixime and clavulanic acid as active agents
EP11712063A EP2528586A1 (en) 2010-01-29 2011-01-28 Effervescent formulations comprising cefixime and clavulanic acid as active agents
PCT/TR2011/000026 WO2011093822A1 (en) 2010-01-29 2011-01-28 Effervescent formulations comprising cefixime and clavulanic acid as active agents

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
TR2010/00687A TR201000687A1 (en) 2010-01-29 2010-01-29 Effervescent formulations containing cefixime and clavulanic acid as active ingredient

Publications (1)

Publication Number Publication Date
TR201000687A1 true TR201000687A1 (en) 2011-08-22

Family

ID=43853203

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2010/00687A TR201000687A1 (en) 2010-01-29 2010-01-29 Effervescent formulations containing cefixime and clavulanic acid as active ingredient

Country Status (3)

Country Link
EP (1) EP2528586A1 (en)
TR (1) TR201000687A1 (en)
WO (2) WO2011093822A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011142730A1 (en) * 2010-05-14 2011-11-17 Mahmut Bilgic Pharmaceutical composition comprising cefixime and clavulanic acid derivative compound
WO2011152806A1 (en) * 2010-06-03 2011-12-08 Mahmut Bilgic Production method for the effervescent formulation comprising cephalosporin and potassium clavulanate
WO2013109228A1 (en) * 2012-01-18 2013-07-25 Mahmut Bilgic Formulations comprising cefixime as active agent
WO2014126541A1 (en) * 2013-02-14 2014-08-21 Bilgiç Mahmut Pharmaceutical compositions used in treating bacterial infections

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1508977A (en) 1974-04-20 1978-04-26 Beecham Group Ltd Beta-lactam antibiotic from streptomyces clavuligerus
US4409214A (en) 1979-11-19 1983-10-11 Fujisawa Pharmaceutical, Co., Ltd. 7-Acylamino-3-vinylcephalosporanic acid derivatives and processes for the preparation thereof
AU5863894A (en) 1993-01-22 1994-08-15 Smithkline Beecham Plc Pharmaceutical formulations comprising clavulanic acid alone or in combination with other beta-lactam antibiotics
GB9408117D0 (en) 1994-04-23 1994-06-15 Smithkline Beecham Corp Pharmaceutical formulations
DE69617036T2 (en) 1995-09-07 2002-07-11 Smithkline Beecham Corp USE OF A PEDIATRIC PHARMACEUTICAL FORMULATION CONTAINING AMOXICILLIN AND CLAVULANATE
NZ512609A (en) * 1996-02-29 2003-03-28 Fujisawa Pharmaceutical Co Synthetic sweeteners, their production and uses thereof
GB9815532D0 (en) * 1998-07-17 1998-09-16 Lek Pharmaceutical & Cvhemical Pharmaceutical suspension formulation
AU2869100A (en) * 1999-02-26 2000-09-14 Biovail International Ltd. Storage stable amoxycillin and clavulanate suspension composition
CO5170471A1 (en) 1999-04-13 2002-06-27 Beecham Pharmaceutical Pte Ltd MODIFIED RELEASE TABLETS INCLUDING AMOXYLIN AND POTASSIUM CLAVULANATE
CN100417383C (en) * 2006-03-07 2008-09-10 中国药科大学 Effervescent tablet containing cefixime and its preparing method
EP2015755A4 (en) * 2006-04-28 2010-02-24 Wockhardt Ltd Improvements in therapy for treating resistant bacterial infections
WO2011142730A1 (en) * 2010-05-14 2011-11-17 Mahmut Bilgic Pharmaceutical composition comprising cefixime and clavulanic acid derivative compound

Also Published As

Publication number Publication date
EP2528586A1 (en) 2012-12-05
WO2011093822A1 (en) 2011-08-04
WO2011093829A1 (en) 2011-08-04

Similar Documents

Publication Publication Date Title
ES2683355T3 (en) Prodrugs of smokers and their use in the treatment of various diseases
HRP20150770T1 (en) Therapeutic combination comprising dolutegravir, abacavir and lamivudine
WO2011093826A3 (en) Effervescent formulations comprising cefaclor and clavulanic acid as active agents
WO2011139684A3 (en) Nicotine-containing pharmaceutical compositions
MY167423A (en) Quinoline carboxamide and quinoline carbonitrile derivatives as mglur2-negative allosteric modulators,compositions,and their use
EA201590449A1 (en) ORAL PREPARED MEDICINE COMPOSITION
JP2012255026A5 (en)
NZ605887A (en) Pharmaceutical dosage form comprising 6’-fluoro-(n-methyl- or n,n-dimethyl-)-4-phenyl-4’,9’-dihydro-3’h-spiro[cyclohexane-1,1’-pyrano[3,4,b]indol]-4-amine for the treatment of neuropathic pain
RU2015104537A (en) METHODS FOR TREATING STOMAL TUMORS OF THE GASTROINTESTINAL TRACT
IN2014MN01755A (en)
NZ602510A (en) Treatment of lupus nephritis using laquinimod
WO2011107855A3 (en) Sustained release oral liquid suspension dosage form
EA201200618A1 (en) CHROMENON DERIVATIVES WITH ANTI-TUMOR ACTIVITY
MX2012000275A (en) Acid pump antagonist for treatment of diseases associated with abnormal gastrointestinal movement.
EA201590797A1 (en) PREPARATIONS WITH THE MODIFIED PROBE RELEASE
MY160652A (en) Pharmaceutical composition for oral administration
EA201691490A1 (en) PHARMACEUTICAL COMPOSITION CONTAINING BRINZOLAMIDE
WO2011151722A3 (en) Methods and compositions for oral pharmaceutical therapy
RU2014129508A (en) NEW COMBINATION
TR201000687A1 (en) Effervescent formulations containing cefixime and clavulanic acid as active ingredient
JP2012518646A5 (en)
EA201490166A1 (en) Fluorinated arylalkyl-aminocarboxamide derivatives
MA32406B1 (en) Compounds containing tricyclic azotes and their use as antibacterials
EA201390950A1 (en) HOMOGENEOUS PHARMACEUTICAL ORAL DOSAGE FORMS CONTAINING LERKANIDIPIN AND ENALAPRIL OR THEIR PHARMACEUTICALLY ACCEPTABLE SALTS TOGETHER WITH ORGANIC ACID
DE602006012310D1 (en) PHARMACEUTICAL FORMULATIONS CONTAINING ABSORBENT PHARMACEUTICAL ACTIVITIES CONTAINING TITANIUM DIOXIDE NANOPARTICLES